SFCE-RAPIRI Phase I Study of Rapamycin Plus Irinotecan: A New Way to Target Intra-Tumor Hypoxia in Pediatric Refractory CancersSarah Jannier, Natacha Entz‐Werlé|Cancers|2020Cited by 7